Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in mCRPC with Visceral Metastases
NCT01834651Phase 2Completed
- Start
- Apr 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoint: Clinical Benefit Rate From Cabozantinib (XL184) at 12 weeks. Started Apr 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01834651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01834651.